1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Cancer - Drugs In Development, 2022, provides an overview of the Vaginal Cancer (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Vaginal cancer is a rare cancer that occurs in vagina. Symptoms includes watery vaginal discharge, a lump or mass in vagina, painful urination, constipation and pelvic pain, vaginal bleeding. Risk factors include age, Smoking, HIV infection and vaginal intraepithelial neoplasia. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Vaginal Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Vaginal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Vaginal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Vaginal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and IND/CTA Filed stages are 7, 22, 8 and 1 respectively.
Vaginal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Vaginal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Vaginal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Vaginal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Vaginal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Vaginal Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Vaginal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Vaginal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Vaginal Cancer - Overview
- Vaginal Cancer - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Vaginal Cancer - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Vaginal Cancer - Companies Involved in Therapeutics Development
- AstraZeneca Plc
- Beijing Kangle Guardian Biotechnology Co Ltd
- Beijing Kangleweishi Biotechnology Co Ltd
- Bristol-Myers Squibb Co
- Chengdu Institute of Biological Products Co Ltd
- Eisai Co Ltd
- F. Hoffmann-La Roche Ltd
- Gilead Sciences Inc
- Hookipa Pharma Inc
- ISA Pharmaceuticals BV
- Merck & Co Inc
- Merck KGaA
- Ology Bioservices Inc
- Ono Pharmaceutical Co Ltd
- PDS Biotechnology Corp
- Perseus Proteomics Inc
- Pionyr Immunotherapeutics Inc
- Precigen Inc
- Privo Technologies Inc
- RemeGen Co Ltd
- Shanghai Bovax Biotechnology Co Ltd
- Shanghai Zerun Biotechnology Co Ltd
- SinoCelltech Group Ltd
- SQZ Biotechnologies Co
- Suzhou Neupharma Co Ltd
- Transcenta Holding Ltd
- Transgene SA
- Turnstone Biologics Inc
- Vaginal Cancer - Drug Profiles
- adavosertib - Drug Profile
- Product Description
- Mechanism Of Action
- bevacizumab - Drug Profile
- Product Description
- Mechanism Of Action
- bintrafusp alfa - Drug Profile
- Product Description
- Mechanism Of Action
- cisplatin - Drug Profile
- Product Description
- Mechanism Of Action
- decitabine - Drug Profile
- Product Description
- Mechanism Of Action
- disitamab vedotin - Drug Profile
- Product Description
- Mechanism Of Action
- durvalumab - Drug Profile
- Product Description
- Mechanism Of Action
- durvalumab + tremelimumab - Drug Profile
- Product Description
- Mechanism Of Action
- HB-201 - Drug Profile
- Product Description
- Mechanism Of Action
- HB-202 - Drug Profile
- Product Description
- Mechanism Of Action
- HPV-16 E7 - Drug Profile
- Product Description
- Mechanism Of Action
- human papillomavirus (9 valent) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- human papillomavirus (9-valent) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- human papillomavirus [serotypes 16, 18, 58] (trivalent) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- human papillomavirus [serotypes 6, 11, 16, 18, 31, 33, 45, 52 and 58] (9-valent) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- human papillomavirus [serotypes 6, 11, 16, 18] (quadrivalent) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- human papillomavirus [serotypes 6,11,16,18,31,33,45,52,58,59 and 68] (11-valent) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- human papillomavirus [serotypes 6,11,16,18,31,33,45,52,58] (9-valent) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- ipilimumab + nivolumab - Drug Profile
- Product Description
- Mechanism Of Action
- M-9241 - Drug Profile
- Product Description
- Mechanism Of Action
- MEDI-0457 - Drug Profile
- Product Description
- Mechanism Of Action
- nivolumab - Drug Profile
- Product Description
- Mechanism Of Action
- NTO-1151 - Drug Profile
- Product Description
- Mechanism Of Action
- Oncolytic Virus to Target E6 and E7 for Human Papillomavirus (HPV) Associated Solid Tumors - Drug Profile
- Product Description
- Mechanism Of Action
- PDS-0101 - Drug Profile
- Product Description
- Mechanism Of Action
- peltopepimut-s - Drug Profile
- Product Description
- Mechanism Of Action
- pembrolizumab - Drug Profile
- Product Description
- Mechanism Of Action
- PPMX-T002 - Drug Profile
- Product Description
- Mechanism Of Action
- PRGN-2009 - Drug Profile
- Product Description
- Mechanism Of Action
- PRV-211 - Drug Profile
- Product Description
- Mechanism Of Action
- PY-159 - Drug Profile
- Product Description
- Mechanism Of Action
- PY-314 - Drug Profile
- Product Description
- Mechanism Of Action
- RX-208 - Drug Profile
- Product Description
- Mechanism Of Action
- SCT-1000 - Drug Profile
- Product Description
- Mechanism Of Action
- SQZ-AACs (Oncology) - Drug Profile
- Product Description
- Mechanism Of Action
- SQZ-APCs (Oncology) - Drug Profile
- Product Description
- Mechanism Of Action
- tipapkinogene sovacivec - Drug Profile
- Product Description
- Mechanism Of Action
- TST-005 - Drug Profile
- Product Description
- Mechanism Of Action
- Vaginal Cancer - Dormant Projects
- Vaginal Cancer - Product Development Milestones
- Featured News & Press Releases
- Sep 27, 2018: Vaccine, anti-PD1 drug show promise against incurable HPV-related cancers
- Jun 17, 2015: GARDASIL9: New HPV vaccine approved in the European Union
- Apr 01, 2015: Merck's HPV Vaccine, GARDASIL 9, now available in Canada
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Vaginal Cancer, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Vaginal Cancer - Pipeline by AstraZeneca Plc, 2022
- Vaginal Cancer - Pipeline by Beijing Kangle Guardian Biotechnology Co Ltd, 2022
- Vaginal Cancer - Pipeline by Beijing Kangleweishi Biotechnology Co Ltd, 2022
- Vaginal Cancer - Pipeline by Bristol-Myers Squibb Co, 2022
- Vaginal Cancer - Pipeline by Chengdu Institute of Biological Products Co Ltd, 2022
- Vaginal Cancer - Pipeline by Eisai Co Ltd, 2022
- Vaginal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, 2022
- Vaginal Cancer - Pipeline by Gilead Sciences Inc, 2022
- Vaginal Cancer - Pipeline by Hookipa Pharma Inc, 2022
- Vaginal Cancer - Pipeline by ISA Pharmaceuticals BV, 2022
- Vaginal Cancer - Pipeline by Merck & Co Inc, 2022
- Vaginal Cancer - Pipeline by Merck KGaA, 2022
- Vaginal Cancer - Pipeline by Ology Bioservices Inc, 2022
- Vaginal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, 2022
- Vaginal Cancer - Pipeline by PDS Biotechnology Corp, 2022
- Vaginal Cancer - Pipeline by Perseus Proteomics Inc, 2022
- Vaginal Cancer - Pipeline by Pionyr Immunotherapeutics Inc, 2022
- Vaginal Cancer - Pipeline by Precigen Inc, 2022
- Vaginal Cancer - Pipeline by Privo Technologies Inc, 2022
- Vaginal Cancer - Pipeline by RemeGen Co Ltd, 2022
- Vaginal Cancer - Pipeline by Shanghai Bovax Biotechnology Co Ltd, 2022
- Vaginal Cancer - Pipeline by Shanghai Zerun Biotechnology Co Ltd, 2022
- Vaginal Cancer - Pipeline by SinoCelltech Group Ltd, 2022
- Vaginal Cancer - Pipeline by SQZ Biotechnologies Co, 2022
- Vaginal Cancer - Pipeline by Suzhou Neupharma Co Ltd, 2022
- Vaginal Cancer - Pipeline by Transcenta Holding Ltd, 2022
- Vaginal Cancer - Pipeline by Transgene SA, 2022
- Vaginal Cancer - Pipeline by Turnstone Biologics Inc, 2022
- Vaginal Cancer - Dormant Projects, 2022
- Number of Products under Development for Vaginal Cancer, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AstraZeneca Plc
- Beijing Kangle Guardian Biotechnology Co Ltd
- Beijing Kangleweishi Biotechnology Co Ltd
- Bristol-Myers Squibb Co
- Chengdu Institute of Biological Products Co Ltd
- Eisai Co Ltd
- F. Hoffmann-La Roche Ltd
- Gilead Sciences Inc
- Hookipa Pharma Inc
- ISA Pharmaceuticals BV
- Merck & Co Inc
- Merck KGaA
- Ology Bioservices Inc
- Ono Pharmaceutical Co Ltd
- PDS Biotechnology Corp
- Perseus Proteomics Inc
- Pionyr Immunotherapeutics Inc
- Precigen Inc
- Privo Technologies Inc
- RemeGen Co Ltd
- Shanghai Bovax Biotechnology Co Ltd
- Shanghai Zerun Biotechnology Co Ltd
- SinoCelltech Group Ltd
- SQZ Biotechnologies Co
- Suzhou Neupharma Co Ltd
- Transcenta Holding Ltd
- Transgene SA
- Turnstone Biologics Inc
